Reset filter
Nyckelord
Gynekologia ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
    1. 7.1. Anestesi
    1. 7.2. Dermatologi
    1. 7.3. HNO
    1. 7.4. Geriatrik
    1. 7.5. Gynekologi och obstetrik
    1. 7.6. Invärtes medicin
      1. Hematologi
      1. Infektionssjukdomar
      1. Kardiologi och angiologi
      1. Pneumologi
      1. Gastroenterologi
      1. Nefrologi
      1. Endokrinologi och ämnesomsättning
      1. Reumatologi
    1. 7.7. Neurologi
    1. 7.8. Oftalmologi
    1. 7.9. Palliativ medicin
    1. 7.10. Patologi och rättsmedicin
    1. 7.11. Pediatrik
    1. 7.12. Psykiatri och psykosomatik
    1. 7.13. Radiologi
    1. 7.14. Kirurgi
      1. Allmänkirurgi och bukkirurgi
      1. Neurokirurgi
      1. Plastikkirurgi
      1. Hjärt- och thoraxkirurgi
      1. Akutkirurgi och ortopedi
      1. Kärlkirurgi
    1. 7.15. Urologi
    1. 7.16. Odontologi samt mun-, käk och ansiktskirurgi
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

1082 Sökresultat.
Relevans Bedömning Nya först Gamla först

CHEST X-RAY (AP AND LATERAL) Roche H0650g Breast Cancer - CHEST X-RAY (AP AND LATERAL)

- 2017-05-16 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Chest X-Ray
Study part: Chest X- ray. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

STUDY TERMINATION CHEST X-RAY (AP AND LATERAL) Roche H0650g Breast Cancer - STUDY TERMINATION CHEST X-RAY (AP AND LATERAL)

- 2017-05-20 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Chest X-Ray
Study part: Study Termination Chest X- ray. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

HIS cancer conference gynecology breast cancer - HIS

- 2013-05-15 - 1 Formulär, 8 Item-grupper, 49 Dataelement, 2 Språk
Item-grupper: Patientenaufkleber groß, Tumorkonferenz, Angaben zum Patienten, Verlauf, Pathologie Befund, Fragestellung, Subformular, Empfehlungen der Tumorkonferenz
HIS cancer conference gynecology breast cancer

HIS Registration cancer conference - gynecology breast cancer - HIS

- 2021-04-13 - 1 Formulär, 3 Item-grupper, 48 Dataelement, 2 Språk
Item-grupper: Admininstrative Daten, Anmeldung TB Mamma, Zytologie-Befunde
HIS Registration cancer conference - gynecology breast cancer

HIS documentation cancer conference - gynecology breast cancer - HIS

- 2013-05-15 - 1 Formulär, 8 Item-grupper, 86 Dataelement, 2 Språk
Item-grupper: Admininstrative Daten, Dokumentation TB Mamma, klin. TNM-Stadium, vorh. path.TNM-Stadium, TNM-Stadium der Patho, endgültiges TNM-Stadium, Geplante Therapie, Weiteres
HIS documentation cancer conference - gynecology breast cancer

Eligibility Breast Cancer NCT01052740

- 2017-11-03 - 1 Formulär, 2 Item-grupper, 18 Dataelement, 1 Språk
Item-grupper: Criteria, Exclusion Criteria
X-Ray Mammography Standard of Care Protocol; ODM derived from: https://clinicaltrials.gov/show/NCT01052740

Perinatal Intensive Care Gynaecology UKM - Perinatal Intensive Care

- 2021-09-20 - 1 Formulär, 9 Item-grupper, 70 Dataelement, 2 Språk
Item-grupper: Patient demographics, Cervical Score, Amnioscopy, Birth, Delivery, Sonography, Diagnostic, Examination, Footer module
Perinatal Intensive Care form converted to ODM format. Routine documentation of University Hospital of Münster. Publication granted by Prof. Dr. med. Ludwig Kiesel

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Screening

- 2020-10-13 - 1 Formulär, 24 Item-grupper, 273 Dataelement, 1 Språk
Item-grupper: Date of visit, Assessment Date, Trial Screening, Enrollment, Clinical Trial Subject Unique Identifier, Demography, Eligibility Determination, Inclusion, Exclusion Criteria, disease characteristic, disease characteristic, Neoplasm Metastasis, Electrocardiography, Echocardiography; Multiple gated acquisition scanning, Laboratory Procedures, Central Laboratory; Laboratory Procedures, Local, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Central Laboratory, Data, Disease, Operative Surgical Procedures, Disease, Relationships, Disease, Clinical Trials, Therapeutic procedures, Relationships, Disease, Cancer treatment, Prior Therapy, Neurologic Examination, Vital signs, Prior Radiation Therapy, Prior Radiation Therapy, Central Nervous System
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

UFK HD: Gynäkologische Tumore - Anamnesis

- 2023-02-13 - 1 Formulär, 3 Item-grupper, 45 Dataelement, 2 Språk
Item-grupper: anamnesis_general, anamnesis_specific, WHO-5
Dieses Projekte soll an der UFK HD im Bereich der gynäkologischen Tumore (1) die strukturierte Datenerfassung gemäß CDISC Standard ermöglich und (2) die klinische Arbeit entlang des Patientinnenweges digitalisieren und zur Arbeitserleichterung für die beteiligten Mitarbeiter:innen führen. Affiliation: Department of Obstetrics and Gynecology, Heidelberg University Hospital

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Cycle 1 - Week 4

- 2020-10-13 - 1 Formulär, 9 Item-grupper, 163 Dataelement, 1 Språk
Item-grupper: Date of visit, Assessment Date, Neurologic Examination, Neurologic Symptoms, Associated with, Neoplasms, Laboratory Procedures, Central Laboratory; Laboratory Procedures, Local, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Central Laboratory, Data, Vital signs, Continuation status, Study
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Day 1 Predose

- 2020-10-13 - 1 Formulär, 6 Item-grupper, 40 Dataelement, 1 Språk
Item-grupper: Date of visit, Assessment Date, Neurologic Examination, Neurologic Symptoms, Associated with, Neoplasms, Vital signs, Randomization, Numbers, Therapeutic regimen
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Eligibility Breast Cancer NCT01067976

- 2021-09-27 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI; ODM derived from: https://clinicaltrials.gov/show/NCT01067976

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial